Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 14NIH 3NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 3

Interventions

Cyclophosphamide 388Specimen Handling 377Magnetic Resonance Spectroscopy 328Radiotherapy 306Biopsy 273Cisplatin 258Carboplatin 255Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 183Bevacizumab 181Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 141Taxes 127Docetaxel 122Chemotherapy, Adjuvant 114Oxaliplatin 113fludarabine phosphate 111Methotrexate 108Rituximab 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Nephrectomy × Clear all
NCT03055013 2026-06-03

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

National Cancer Institute (NCI)

Phase 3 Active not recruiting
819 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

NCT07516366 2026-05-15

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
16 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT02595918 2020-10-23

Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery

National Cancer Institute (NCI)

Phase 1 Terminated
19 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡